NYSE · ABBV
Healthcare · Drug Manufacturers - General
$263.04
Up+$1.24 (+0.47%)
Updated Sep 16, 2026, 12:42 PM
SID Score
7.0/10
Composite research score
Smart Money
53/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ABBV closed at $263.04 after 20 trading sessions, up 1.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $260.00 | $264.81 | $257.795 | $263.04 | 5.12M |
| Sep 14, 2026 | $261.67 | $264.6499 | $260.1001 | $261.77 | 4.51M |
| Sep 11, 2026 | $253.92 | $259.61 | $253.92 | $257.12 | 4.31M |
| Sep 10, 2026 | $251.23 | $255.31 | $249.735 | $255.00 | 4.4M |
| Sep 9, 2026 | $247.73 | $251.18 | $246.7701 | $250.91 | 3.87M |
| Sep 8, 2026 | $251.84 | $254.615 | $248.41 | $248.78 | 5.57M |
| Sep 4, 2026 | $257.96 | $258.91 | $255.58 | $256.46 | 4.73M |
| Sep 3, 2026 | $264.00 | $264.25 | $257.14 | $260.21 | 2.88M |
| Sep 2, 2026 | $262.70 | $262.97 | $257.70 | $261.72 | 4.23M |
| Sep 1, 2026 | $260.99 | $262.265 | $257.79 | $259.99 | 3.87M |
| Aug 31, 2026 | $254.17 | $258.24 | $252.33 | $256.42 | 4.32M |
| Aug 28, 2026 | $258.67 | $259.00 | $255.0797 | $255.48 | 3.22M |
| Aug 27, 2026 | $260.81 | $262.4977 | $257.25 | $258.15 | 4.76M |
| Aug 26, 2026 | $264.60 | $265.00 | $260.31 | $262.90 | 3.31M |
| Aug 25, 2026 | $264.50 | $266.905 | $263.025 | $265.79 | 3.67M |
| Aug 24, 2026 | $263.99 | $266.0395 | $262.07 | $264.52 | 3.88M |
| Aug 21, 2026 | $260.70 | $266.84 | $260.101 | $264.96 | 5.16M |
| Aug 20, 2026 | $265.69 | $265.93 | $260.4812 | $261.83 | 5.23M |
| Aug 19, 2026 | $261.51 | $266.965 | $259.55 | $265.97 | 5.54M |
| Aug 18, 2026 | $253.93 | $259.18 | $252.41 | $258.92 | 5.01M |
The latest Smart Investors Daily articles mentioning ABBV.
ABBV research
Company profile and research snapshot.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Buy | — |
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 17, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Aug 11, 2026 | BNP Paribas | Neutral | — |
Generated Sep 15, 2026, 9:00 PM
AbbVie shares gained 0.47% today as investors digest a series of strategic announcements focused on post-HUMIRA growth initiatives and pipeline expansion. The pharmaceutical giant is actively positioning itself for sustainable revenue growth through partnerships, clinical advances, and brand diversification efforts.
Bottom line: AbbVie is executing a methodical transition from HUMIRA dependency through strategic acquisitions, pipeline advancement, and diversification into faster-growing therapeutic areas like migraine and aesthetics. While today's modest gains reflect investor confidence in these moves, successful execution of the post-HUMIRA strategy and continued pipeline delivery remain critical watch items for long-term shareholders. The high dividend yield provides downside support, but investors should monitor revenue trends and biosimilar market share developments closely.
Yahoo · Sep 15, 2026
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)’s ratings from Peer Perform, with Wolfe assigning them similar $300 price targets. The firm’s logic in each case was based on a comparable set of factors: pipelines that the market appears to […]
Yahoo · Sep 15, 2026
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E
SeekingAlpha · Sep 15, 2026
AbbVie Inc. (ABBV) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:00 AM EDTCompany ParticipantsRobert Michael - CEO &...
Yahoo · Sep 15, 2026
AbbVie (NYSE: ABBV), together with BioLabs University of Toronto, today announced the opening of applications for the AbbVie Biotech Innovators Award during the Life Sciences Ontario Ideas to Action Forum in Toronto. The award aims to support the growth of Ontario's life sciences sector by helping promising early-stage biotechnology companies accelerate the development of innovative healthcare solutions.
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. shares traded at $263.01, reflecting a daily decline of 1.32%, per SID market data. Despite the session's pullback, the stock has demonstrated consistent upward momentum across multiple timeframes, gaining 4.37% over the past month, 14.95% over three months, and 16.25% over the trailing twelve months, according to Massive/Polygon data. ABBV currently trades above both its 50-day moving average of $254.52 and its 200-day moving average of $228.96, indicating a sustained bullish trend structure. The 14-day relative strength index registers at 46.9, placing the stock in neutral territory and suggesting neither overbought nor oversold conditions. AbbVie carries a beta of 0.334, reflecting significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 6.4 million shares, supporting adequate liquidity. The company's market capitalization currently sits at approximately $410.1 billion, per SID market data.
AbbVie Inc. currently trades at a price-to-earnings ratio of 97.75, a figure elevated relative to Healthcare sector peers, according to SID market data. The elevated P/E reflects the impact of significant non-cash charges and amortization expenses tied to acquisitions, which weigh on reported GAAP earnings. The company's PEG ratio stands at 1.25, suggesting the stock is modestly valued relative to its expected earnings growth trajectory. AbbVie offers a dividend yield of approximately 2.87%, per SEC filings, reinforcing its appeal among income-focused investors within the large-cap pharmaceutical space. Notably, the company's price-to-book ratio is negative at -126.33, a direct consequence of accumulated goodwill write-downs and share repurchase programs that have driven shareholders' equity into negative territory. This negative book value is not uncommon among highly acquisitive pharmaceutical firms. AbbVie's $410.1 billion market capitalization positions it among the largest Healthcare companies globally.
AbbVie Inc. registers a composite smart money score of 53, signaling a neutral overall stance among sophisticated market participants, per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained accumulation by large fund managers across recent reporting periods. The insider trading component scores 18 out of 25, supported by two insider purchases and zero insider sales recorded over the past 90 days, according to SEC Form 4 filings. This buy-only insider activity suggests corporate officers and directors maintain confidence in the company's forward outlook at current price levels. Conversely, the dark pool activity score sits at a modest 9.7 out of 25, indicating below-average off-exchange institutional buying interest. Congressional trading activity is minimal, scoring just 0.8 out of 25, per 13F institutional filings and congressional disclosure records. The divergence between exceptionally strong institutional ownership signals and subdued dark pool activity presents a mixed but modestly constructive smart money profile for ABBV.
AbbVie Inc. has delivered a mixed earnings trajectory over recent quarters, according to company earnings reports. In the most recently completed quarter reported on February 4, 2026, AbbVie posted earnings per share of $2.71, exceeding the consensus estimate of $2.66 by $0.05. However, the subsequent quarter reported on April 29 showed EPS of $2.65, falling marginally short of the $2.66 estimate by one cent. The quarter reported on July 31 reflected a more pronounced miss, with actual EPS of $3.65 coming in $0.12 below the $3.77 analyst estimate. Looking ahead, the upcoming quarter carries a consensus estimate of $3.01 per share, per analyst estimates. The pattern of narrowing beats followed by misses warrants monitoring as AbbVie navigates its post-Humira biosimilar competition landscape and integrates recent acquisitions. Revenue diversification through Skyrizi and Rinvoq remains central to the company's growth narrative.
Wall Street consensus on AbbVie Inc. remains predominantly constructive, with recent analyst activity reflecting maintained or upgraded ratings, per Wall Street analyst reports. On September 10, 2026, HSBC reiterated its Buy rating on ABBV. Piper Sandler maintained an Overweight rating on August 20, while Wells Fargo similarly reiterated its Overweight stance on August 17. The most notable recent action came from Wolfe Research on August 13, which upgraded ABBV to Outperform from Peer Perform, representing a meaningful positive shift in sentiment from a widely followed healthcare research franchise. BNP Paribas maintained its Neutral rating on August 11, representing the sole non-bullish stance among the five most recent coverage updates, according to SID consensus data. Of the five recent analyst actions tracked, four reflect bullish or positive positioning, while one remains neutral. No analysts have issued bearish ratings or downgrades during this period, underscoring broad institutional confidence in AbbVie's strategic and financial trajectory.
The latest Smart Investors Daily articles mentioning ABBV.
